Progenity PROG shares are trading lower on Monday after Wells Fargo downgraded the stock from Overweight to Underweight and lowered its price target from $11 to $5 per share.
Progenity is a biotechnology company. It is engaged in developing and commercializing molecular testing products. The company is translating innovation into precision medicine through diagnostic and therapeutic development platforms based on genomics, proteomics, and microbiomics. The firm generates its revenue from molecular laboratory tests, principally from the sale of Innatal, Preparent, and pathology molecular testing.
Progenity shares were trading down 7.25% at $5.76. The stock has a 52-week high of $15.92 and low of $3.08.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
